QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:CRDL

Cardiol Therapeutics - CRDL Stock Forecast, Price & News

$0.66
-0.04 (-5.68%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.66
▼
$0.71
50-Day Range
$0.49
▼
$0.81
52-Week Range
$0.47
▼
$2.08
Volume
58,820 shs
Average Volume
83,626 shs
Market Capitalization
$42.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Cardiol Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
502.0% Upside
$4.00 Price Target
Short Interest
Healthy
0.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.45) to ($0.31) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.28 out of 5 stars

Medical Sector

985th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

165th out of 169 stocks

See Top Rated MarketRank™ Stocks Here
CRDL stock logo

About Cardiol Therapeutics (NASDAQ:CRDL) Stock

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ""ARCHER"" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Receive CRDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRDL Stock News Headlines

January 17, 2023 | finance.yahoo.com
Cardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditis
January 17, 2023 | proactiveinvestors.com
Cardiol Therapeutics enrolls first patient in Phase II CardiolRx study on recurrent pericarditis
February 6, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
December 14, 2022 | proactiveinvestors.com
Cardiol Therapeutics commences Phase II study of CardiolRx for treatment of Recurrent Pericarditis
December 12, 2022 | proactiveinvestors.com
Cardiol Therapeutics kicks off a multi-center Phase II pilot study of CardiolRx for the treatment of recurrent pericarditis
November 7, 2022 | proactiveinvestors.com
Cardiol Therapeutics unveils new study data highlighting protective effects of CardiolRx in acute pericarditis
October 25, 2022 | seekingalpha.com
Cardiol to abandon COVID study of cannabis drug to focus on heart diseases trials
August 3, 2022 | finance.yahoo.com
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis
February 6, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
July 12, 2022 | finance.yahoo.com
Cardiol Therapeutics Inc. (TSE:CRDL): Are Analysts Optimistic?
June 9, 2022 | finance.yahoo.com
Cardiol Therapeutics Announces At-The-Market Equity Offering Program
June 1, 2022 | benzinga.com
Cardiol Therapeutics (NASDAQ:CRDL), Earnings Estimates, EPS, and Revenue
May 19, 2022 | proactiveinvestors.com.au
Cardiol Therapeutics appoints Teri Loxam and CFO Chris Waddick to its board of directors
May 17, 2022 | proactiveinvestors.com.au
Cardiol Therapeutics receives US FDA authorization for Phase II study of CardiolRx for recurrent pericarditis
May 17, 2022 | proactiveinvestors.com
Cardiol Therapeutics gets FDA go ahead for Investigational New Drug Application for CardiolRx
May 17, 2022 | finance.yahoo.com
Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis
May 2, 2022 | finance.yahoo.com
We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn
March 15, 2022 | proactiveinvestors.com
Cardiol Therapeutics says Jennifer M. Chao has been appointed as director of the company
March 15, 2022 | finance.yahoo.com
Cardiol Therapeutics Appoints Jennifer M. Chao to Its Board of Directors
January 20, 2022 | seekingalpha.com
NeuroMetrix, Mainz lead healthcare gainers; Dyne, Allarity among losers
January 6, 2022 | nasdaq.com
Cardiol Therapeutics Inc - Class A Shares Near 52-Week Low - Market Mover
November 5, 2021 | proactiveinvestors.com
Cardiol Therapeutics raises US$50M to advance research and clinical development initiatives
November 5, 2021 | proactiveinvestors.com
Cardiol Therapeutics completes massive financing adding 50 million US to the treasury
November 5, 2021 | finance.yahoo.com
Cardiol Therapeutics Announces Closing of US$50 Million Public Offering
October 25, 2021 | finance.yahoo.com
Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis
September 16, 2021 | finance.yahoo.com
Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
August 26, 2021 | ca.finance.yahoo.com
Stocks in play: Cardiol Therapeutics Inc.
See More Headlines
Receive CRDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRDL Company Calendar

Last Earnings
11/10/2022
Today
2/06/2023
Next Earnings (Estimated)
3/22/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRDL
CUSIP
N/A
CIK
1702123
Web
www.cardiolrx.com
Phone
(289) 910-0850
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+502.0%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.38)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-25,240,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-44.32%
Return on Assets
-38.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.02
Quick Ratio
7.02

Sales & Book Value

Annual Sales
$60,000.00
Price / Sales
709.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.98 per share
Price / Book
0.68

Miscellaneous

Outstanding Shares
64,040,000
Free Float
60,681,000
Market Cap
$42.55 million
Optionable
Not Optionable
Beta
-0.19

Key Executives

  • David G. Elsley
    President, Chief Executive Officer & Director
  • Bernard Lim
    Chief Operating Officer
  • Christopher J. Waddick
    Chief Financial Officer, Secretary & Director
  • Andrew Hamer
    Chief Medical Officer, Head-Research & Development
  • Blagoja Ristevski
    Director-Chemical Engineering & Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













CRDL Stock - Frequently Asked Questions

What is Cardiol Therapeutics' stock price forecast for 2023?

0 Wall Street research analysts have issued 1 year price objectives for Cardiol Therapeutics' shares. Their CRDL share price forecasts range from $1.00 to $7.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 502.0% from the stock's current price.
View analysts price targets for CRDL or view top-rated stocks among Wall Street analysts.

How have CRDL shares performed in 2023?

Cardiol Therapeutics' stock was trading at $0.51 at the beginning of 2023. Since then, CRDL shares have increased by 30.3% and is now trading at $0.6644.
View the best growth stocks for 2023 here.

When is Cardiol Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our CRDL earnings forecast.

How were Cardiol Therapeutics' earnings last quarter?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) released its quarterly earnings results on Thursday, November, 10th. The company reported ($0.10) earnings per share for the quarter.

What is Cardiol Therapeutics' stock symbol?

Cardiol Therapeutics trades on the NASDAQ under the ticker symbol "CRDL."

Who are Cardiol Therapeutics' major shareholders?

Cardiol Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.14%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Cardiol Therapeutics?

Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiol Therapeutics' stock price today?

One share of CRDL stock can currently be purchased for approximately $0.66.

How much money does Cardiol Therapeutics make?

Cardiol Therapeutics (NASDAQ:CRDL) has a market capitalization of $42.55 million and generates $60,000.00 in revenue each year. The company earns $-25,240,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

How can I contact Cardiol Therapeutics?

The official website for the company is www.cardiolrx.com. The company can be reached via phone at (289) 910-0850 or via email at trevor.burns@cardiolrx.com.

This page (NASDAQ:CRDL) was last updated on 2/6/2023 by MarketBeat.com Staff